Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 10/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.39 |
| ▸ | CNR1 | P21554 | 4/20 | 0.38 |
| ▸ | GSTO1 | P78417 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4131367 | 0.88 | CNR2 (0.41) | CNR2POLBL3MBTL1SMN1; SMN2USP2 | |
| SCHEMBL4148569 | 0.87 | GSTO1 (0.43) | CNR2POLBL3MBTL1SMN1; SMN2USP2 | |
| SCHEMBL4136637 | 0.82 | CNR2 (0.39) | CNR2SMN1; SMN2USP2CNR1ALDH1A1 | |
| SCHEMBL4136648 | 0.82 | CNR2 (0.39) | CNR2SMN1; SMN2USP2CNR1ALDH1A1 | |
| SCHEMBL4134999 | 0.80 | GSTO1 (0.44) | POLBL3MBTL1GSTO1ALDH1A1HPGD | |
| SCHEMBL4140628 | 0.78 | TP53 (0.35) | CNR2CNR1ALDH1A1LMNA | |
| SCHEMBL4140623 | 0.78 | TP53 (0.35) | CNR2CNR1ALDH1A1LMNA | |
| SCHEMBL4148564 | 0.76 | CCR1 (0.40) | POLBSMN1; SMN2USP2GSTO1ALDH1A1 | |
| SCHEMBL4145496 | 0.75 | NPY5R (0.48) | L3MBTL1ALDH1A1 | |
| SCHEMBL4136888 | 0.73 | CNR2 (0.39) | CNR2SMN1; SMN2USP2CNR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | SMITHKLINE BEECHAM CORPORATION | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105259-A1 | Acyclic 1,4-Diamines and Uses Thereof | TRPV4, TRPC4, TRPV1 | CNR2 57/4885POLB 4857/4885L3MBTL1 3940/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.